Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.91 |
| ▸ | CYP2C9 | P11712 | 15/20 | 0.91 |
| ▸ | CYP2C19 | P33261 | 13/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204450 | 1.00 | HSD11B1 (0.91) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL117830 | 0.95 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL117831 | 0.95 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL15254947 | 0.89 | HSD11B1 (0.88) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL12072794 | 0.89 | HSD11B1 (0.88) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL12072796 | 0.89 | HSD11B1 (0.88) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL15254229 | 0.89 | HSD11B1 (0.88) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3218954 | 0.89 | HSD11B1 (0.90) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3218945 | 0.89 | HSD11B1 (0.90) | HSD11B1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL15254666 | 0.88 | HSD11B1 (0.86) | HSD11B1CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202857-B2 | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202857-B2 | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100041637-A1 | 1,3-Oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041637-A1 | 1,3-Oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041637-A1 | 1,3-Oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885CYP2C9 183/4885CYP2C19 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.